A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients. by Beck, D et al.
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid 
leukemia patients 
 
D Beck1,2, J A I Thoms1,16, C Palu1,16, T Herold3, A Shah1, J Olivier4, L Boelen5, Y Huang1, D Chacon1, 
A Brown6, M Babic6, C Hahn6, M Perugini6, X Zhou7, B J Huntly8, A Schwarzer9, J-H Klusmann9, W 
E Berdel10, B Wörmann11, T Büchner10, W Hiddemann3,12, S K Bohlander13, L B To14, H S Scott6, I 
D Lewis6,14, R J D'Andrea6,1,4, J W H Wong1 and J E Pimanda1,2,15 
1Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of 
New South Wales, Sydney, New South Wales, Australia 
2Centre for Health Technologies and the School of Software, University of Technology, Sydney, NSW, 
Australia 
3Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians 
Universität, Munich, Germany 
4School of Mathematics, UNSW Australia, Sydney, NSW, Australia 
5Department of Medicine, Faculty of Medicine, Imperial College London, London, UK 
6Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, Australia 
7School of Medicine, Wake Forest University, Winston-Salem, NC, USA 
8Department of Haematology, Cambridge Institute for Medical Research, Cambridge, UK 
9Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany 
10Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany 
11Department of Medicine, Hematology, Oncology, Tumor Immunology, Charité—Universitätsmedizin 
Berlin, Berlin, Germany 
12Laboratory for Leukemia Diagnostics, Ludwig Maximilians Universität, Munich, Germany 
13Department of Molecular Medicine and Pathology, University of Auckland, New Zealand 
14Department of Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, SA, Australia 
15Department of Haematology, Prince of Wales Hospital, Randwick, NSW, Australia 
Correspondence: Dr D Beck or Dr JWH Wong or Professor JE Pimanda, Adult Cancer Program, Lowy 
Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, 
New South Wales 2052, Australia. E-mail: d.beck@unsw.edu.au or jason.wong@unsw.edu.au or 
jpimanda@unsw.edu.au 
16These authors contributed equally to this work. 
 
Abstract 
Prognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic 
options in acute myeloid leukemia (AML). However, these signatures rely on measuring large 
numbers of genes and often perform poorly when applied to independent cohorts or those with older 
patients. Long intergenic non-coding RNAs (lincRNAs) are emerging as important regulators of cell 
identity and oncogenesis, but knowledge of their utility as prognostic markers in AML is limited. Here 
we analyze transcriptomic data from multiple cohorts of clinically annotated AML patients and report 
that (i) microarrays designed for coding gene expression can be repurposed to yield robust lincRNA 
expression data, (ii) some lincRNA genes are located in close proximity to hematopoietic coding 
genes and show strong expression correlations in AML, (iii) lincRNA gene expression patterns 
distinguish cytogenetic and molecular subtypes of AML, (iv) lincRNA signatures composed of three or 
four genes are independent predictors of clinical outcome and further dichotomize survival in 
European Leukemia Net (ELN) risk groups and (v) an analytical tool based on logistic regression 
analysis of quantitative PCR measurement of four lincRNA genes (LINC4) can be used to determine 
risk in AML. 
 
Introduction 
Acute myeloid leukemia (AML) is a heterogeneous myeloid neoplasm that develops in hematopoietic 
stem and progenitor cells (HSPCs) with altered ability to self-renew, proliferate and differentiate.1 
Leukemic clones often carry cytogenetic abnormalities including translocations, inversions, deletions, 
monosomies and trisomies.1 Recurrent mutations and aberrant expression profiles of coding genes 
and non-coding microRNAs are also commonly found in AML patients with normal cytogenetics (CN-
AML). The karyotype,2 recurrent lesions in the nucleophosmin gene (NPM1),3 tandem internal 
duplications of the fms-related tyrosine kinase 3 (FLT3-ITD)4 and mutations in the transcription factor 
CCAAT/enhancer-binding protein alpha (CEBPA)5 are variably associated with patient remission, 
relapse and survival, and have been integrated into AML prognostic indices such as those developed 
by the United Kingdom Medical Research Council6 or the European Leukemia Net (ELN).7 However, 
the utility of these guidelines for clinical decision-making has only been validated in ~40% of patients 
younger than 60 years (NCI Surveillance, Epidemiology, and End Results Program), and, even within 
this subpopulation, there is substantial prognostic heterogeneity, particularly within the intermediate-
risk group that constitutes the majority of patients.8, 9, 10 
 
The human genome consists of more than three billion nucleotides that encode a relatively small 
percentage of coding (~1.5%) and a larger percentage of non-coding (~75%) transcripts.11 The 
associations between coding genes and the biology, pathogenesis and clinical outcomes of AML have 
been extensively studied. However, the contributions from the large pool of non-coding RNAs to these 
events is largely unknown. In particular, the group of long non-coding RNAs (lncRNAs; >200 
nucleotides) are emerging as key regulators of an increasing number of molecular processes and 
their aberrant expression is correlated with the development of solid tumors and clinical outcome 
(reviewed in Shen et al.12 and Ulitsky and Bartel13). In the hematopoietic system, lncRNAs regulate 
stem cell activity and function in both myeloid and lymphoid differentiation, but their role in leukemia is 
poorly understood. However, lncRNAs associated with the HOX cluster14, 15, 16 and the RUNX1 locus 
have attracted attention in the pathogenesis of acute leukemias.17, 18, 19 To accelerate research in this 
area, data from large multicentre cohort studies are needed to help guide targeted experimental 
investigations and the adoption of lncRNAs as useful clinical biomarkers. 
 
Here we present data on 1664 long intervening/intergenic non-coding RNAs (lincRNAs), a subgroup 
of genes not overlapping coding exons, in 736 patients across three independent patient cohorts. We 
show for the first time that distinct lincRNA expression profiles were associated with recognized 
cytogenetic and mutational subgroups of AML. We also show that an expression signature composed 
of just four lincRNAs (ENSG00000153363, XLOC_013473, ENSG00000255571 and 
ENSG00000260257) had independent prognostic value across all three patient cohorts in a 
multivariable analysis that included age, gender and risk recomendations made by the ELN, which 
incorporates karyotype and the analysis of specific gene mutations. Furthermore, using this signature, 
patients in each ELN risk group could be dichotomized into cohorts with significantly better or worse 
prognosis. This is particularly relevant to patients in ELN intermediate-risk groups, where optimal 
clinical management is often uncertain. To facilitate clinical application, we developed a regression-
based tool to measure and normalize the expression of these four lincRNA and further show its 
prognostic utility in an independent test cohort of 115 clinically annotated AMLs. 
 
Materials and methods 
Patient samples and publicly available microarray data sets 
The patient samples from the Netherlands (NL; N=419), Germany (GER; N=139), the United States of 
America (USA; N=178) and the United Kingdom sets have previously been published, and informed 
consent was given at the corresponding hospitals at the time of diagnosis.20, 21, 22, 23 The study 
protocols were approved by the institutional review boards of corresponding institutes and hospitals. 
The patient samples from the Australia (AUS) set (N=115) were assembled using bone marrow 
mononuclear cell preparations taken at diagnosis with consent via the South Australian Cancer 
Research Biobank with approval from relevant hospital ethics committees in accordance with the 
Declaration of Helsinki. Normal bone marrow samples (N=6) were obtained using an approved 
collection process through the Royal Adelaide Hospital. Research ethics approval was obtained 
through the Royal Adelaide Hospital human ethics committee. Patients were treated using standard 
induction and consolidation chemotherapy protocols. Briefly, patients less than 60 years of age 
received chemotherapy regimens with idarubicin and high-dose cytarabine, and patients over 60 
years received idarubicin and standard dose cytarabine. Consolidation therapy consisted of high-dose 
cytarabine alone or standard dose cytarabine with idarubicin. An overview of the clinical and 
molecular characteristics of patient cohorts is provided in Supplementary Table S1. 
 
Affymetrix U133 Plus 2.0 (HG133P2) array data have previously been published for patients in the 
NL, USA and GER cohorts, and samples from the USA set have also been profiled using the Illumina 
HiSeq2000 (HS2000) platform making HG133P2 and HiSeq2000 data available for the same 159 
samples from the USA set. 
 
Data set description 
A total of nine expression data sets D={d1,...,d8} were analyzed. The data sets d1, d2 and d3 were 
profiled using the Affymetrix HG-133 Plus 2 (HG133P2) microarray technology, d4, d5, d6, d7 and d8 
were profiled using RNA sequencing (RNA-seq) and the data set d8 was profiled using high-
throughput reverse transcriptase polymerase chain reaction (RT-PCR). (1) AML cohort- NL 
set/HG133P2, (2) AML cohort—USA set/HG133P2, (3) AML cohort—GER set/HG133P2, (4) AML 
cohort—USA set/ RNA-seq, (5) Normal hematopoietic cell fractions—BLUEPRINT/RNA-seq, (6) AML 
Cell Lines—Cancer Cell line Encyclopedia/RNA-seq, (7) HSPC—GSE48846/RNA-seq, (8) HSPC—
GSE63569 and (9) AML cohort—AUS set/RT-PCR. We denote the ith sample in a data set d as 
, where Nd is the size of the data set d. 
 
Estimation of lincRNA expression from expression array 
A flowchart of the lincRNA estimation routine (LER) is depicted in Supplementary Figure S1. We 
analyzed the three expression data sets d1,d2,d3 using the LER. In each data set a finite number of 
probes pd={p1|1 1 Od} (Od is the total number of probes tested in data set d) is measured for each 
sample Sd. The raw probe-expression levels were pre-processed using the Partek Genomic Suite 
including background correction, quantile normalization and log2 transformation. The ComBat 
algorithm24 was used to remove experimental variation associated with different array batches, as well 
as biological variation from a gender bias observed in the data. The core of the LER algorithm is the 
association between these expression probes p and known lincRNA transcripts. To generate this 
catalog of probe-to-lincRNA associations, we retrieved the genomic coordinates of currently 
annotated lincRNA transcripts and compared these with the location of the strand-specific HG133P2 
expression probes.25 We considered only lincRNA transcripts T that were probed by at least four 
unique and non-repetitive expression probes in each of the data sets d1, d2, d3; for example, probes 
matching to multiple genes were excluded for the analysis. Given this reduced set of lincRNA 
transcripts, we determined for each lincRNA/a set Tr(l)={T/T is a transcript of l}. There were 1664 
lincRNAs for which this set was non-empty. To define the LER expression value of a lincRNA l, we 
apply a two-tiered approach. Firstly, for a transcript T, we define its expression E (T) as the median 
polished expression value of the probes p overlapping T; for example, if a transcript T overlaps n 
probes p1,...,pn(n 4), with normalized expression levels e1,...,en, the expression level for the 
transcript E(T)=median polish{e1,...,en}. Secondly, we define the expression value of the lincRNAlas 
max{E(T)T∈Tr(l)}. We adopt the notation E(l,d,j) to denote the LER-defined expression value of 
lincRNAlin patient j of data set d. 
 
LincRNA expression profiling using Fluidigm RT-PCR 
To rationally select one target lincRNA signatures (lincRNA-sig) for experimental validation, we first 
calculate the frequency of each lincRNA within the 201 lincRNA-sig (for example, the highest ranked 
lincRNA XLOC_013473 was part of 76/201 lincRNA-sigs) and then scored each lincRNA-sig by the 
mean frequency of all lincRNAs within the lincRNA-sig (Supplementary Table S3). The lincRNA-sig 
consisting of ENSG00000153363, XLOC_013473, ENSG00000255571 and ENSG00000260257 
(LINC4) scored highest with a cumulative frequency of 233 and mean frequency of 58.3. We also 
reanalyzed the NL, GER and the USA sets to identify lincRNA genes with low expression variance 
spanning the expression range of the target lincRNA genes (Supplementary Figure S2). Primers were 
designed for the following reference lincRNA genes: ENSG00000245614, XLOC_004584, 
ENSG00000232388, ENSG00000234608 as well as the reference gene EMC7(ref. 26)(Supplementary 
Table S5). See Supplementary Methods for details. 
 
Results 
Repurposing microarrays to profile lincRNA expression in AML 
Large clinically annotated AML patient cohorts from the NL (N=419), USA (N=178), and GER (N=139) 
have been profiled using standard expression arrays and are currently the largest existing resource to 
study leukemia transcriptomics.20, 21, 22 LincRNAs are typically capped, polyadenylated and often 
spliced and can be profiled using standard expression assays.13 Indeed, typical microarray platforms 
contain probe sets that fully or partially overlap the genomic coordinates of annotated lincRNA genes 
(Figure 1a), and some of these can be repurposed to estimate lincRNA expression.25, 27, 28, 29 To 
measure lincRNA expression levels in large existing leukemia data sets, we implemented the LER 
(Materials and Methods, Supplementary Figure S1). 
 
Repurposing microarrays to profile LincRNA expression in AML. (a) UCSC genome browser 
visualization of lincRNA LINC00925 and flanking coding genes. LINC00925 is robustly expressed in 
some patients (for example, AB-2803 and 2861) but not in others (for example, AB-2915 and 2808). 
LINC00925 overlaps with probes of two probe sets on Affymetrics HG133P2 arrays. (b) Correlations 
between lincRNA expression values estimated from Affymetrics HG133P2 array and measured by 
RNA-seq in the USA set. (i) Pearson correlation coefficients. (ii) −log10 (P-values). (c; i) Correlation 
between expression levels of 1664 lincRNAs in patient AB-2921 in the USA set estimated from an 
Affymetrics HG133P2 array and measured by RNA-seq. (ii) CT values of six selected lincRNAs 
measured by RT-PCR in 27 AML patients (UK set). Note, a high CT corresponds to low expression 
while a low CT corresponds to high expression. These lincRNAs were chosen for their low (1, 2), 
medium (3, 4) and high (5, 6) expression in a. (d) Hierarchical clustering of lincRNA expression levels 
(top) and visualization of correlated coding gene expression levels (bottom) in the USA set. (e) 
Network graph showing lincRNA-to-coding gene relationships generated by the ingenuity pathway 
analysis (IPA). In red/green coding genes positively/negatively correlated with lincRNA genes. The 
network is associated with the ingenuity pathway analysis terms ‘Cancer’, ‘Hematological Disease’ 
and ‘Immunological Disease’. 
 
Interrogation of five expression array platforms identified the Affymetrix HG-133 Plus 2 (HG133P2) 
platform as the most comprehensive resource to study large numbers of lincRNA genes across 
multiple large patient cohorts (Supplementary Table S6). Application of the LER to three existing 
HG133P2 AML data sets revealed that expression levels of 1664 known lincRNA genes could be 
estimated for 736 patients (Supplementary Table S7). This is approximately a fivefold increase 
compared with the 338 lncRNA genes annotated by Affymetrix on the standard HG133P2 array. To 
evaluate the accuracy of these estimates, we first reanalyzed genome-wide expression data of 159 
primary AML samples that have been profiled using both the HG133P2 array and RNA-seq in the 
USA set from The Cancer Genome Atlas project.21 We found that expression levels of lincRNA genes 
measured by these two methods were concordant (P<0.001, Student’s t-test; mean r=0.61, s.d.=0.04; 
Figure 1b). Given the relatively low expression of lincRNAs compared with coding genes,13 these 
correlations were somewhat lower but in a similar range when compared with those from protein-
coding genes (Supplementary Figure S3 and S4). To ensure that this association was not isolated to 
the USA set, we selected two low, two medium and two high expressed lincRNAs from this cohort for 
RT-PCR validation in an independent cohort from the UK30 (Figure 1c). These data confirmed that the 
six lincRNAs, selected by their LER-estimated expression levels (that is, low, medium or high), were 
expressed in the same relative levels when assayed by RT-PCR (that is, qPCR cycle threshold). 
There was a greater concordance of the coefficient of variation when expression was measured by 
strand-specific assays (for example, HG133P2) in different patient cohorts compared with the 
measurements using non-strand-specific assays (for example, RNA-seq) in the same cohort 
(Supplementary Table S8). Taken together, these data suggest that the lincRNA level estimates from 
the HG133P2 array accurately reflect expression levels and that these data could be interrogated for 
new insights in AML. 
 
Expression levels of lincRNAs and their neighboring coding genes are correlated 
The function of most lincRNA genes is not known, but multiple pathways have been suggested in the 
literature.13, 31 One such pathway active in the hematopoietic and other cell systems is the recruitment 
of epigenetic modifiers to enhance or repress the expression of coding genes in close proximity 
(reviewed in Ulitsky and Bartel13). For example, these include the regulation of HOXA genes by 
HOTAIRM1 (antisense to HOXA; epigenetically activates HOXA1/A4/A514). We investigated data from 
the USA set (HG133P2 and RNA-seq) to examine whether these lincRNA–target relationships were 
supported in primary AMLs and found consistent positive correlations between the expression levels 
of HOTAIRM1 and its previously reported targets HOXA1 (R~0.68, P<0.001), HOXA4 (R~0.53, 
P<0.001) and HOXA5 (R~0.54, P<0.001; Supplementary Table S9). We confirmed these correlations 
in the NL and GER sets, suggesting that the HOTAIRM1–HOXA1/A4/A5 relationship is also present in 
primary AMLs (Supplementary Table S9). 
 
To extend this analysis to currently unknown lincRNA–mRNA correlations, we performed an 
equivalent analysis for each of the 1664 lincRNAs with their two closest neighboring coding genes 
(up/downstream) in three independent patient sets, that is, NL, USA and GER (see Materials and 
Methods). We found that the expression levels of a subset of 263 lincRNAs were significantly 
correlated with the expression of 286 neighboring genes (P<0.05; a total of 299 significant 
correlations; Supplementary Table S2) in all three data sets, which was significantly higher than 
expected by chance (P<0.001, confidence interval (132.866, 134.556); Materials and methods). In 
some cases, the directionality of lincRNA–mRNA correlations was not concordant across all three 
patient cohorts, and we excluded such cases (~23%) from further analysis (that is, to 230 genes; 
P<0.001, confidence interval (132.866, 134.556); Materials and Methods; Figure 1d and 
Supplementary Table S2). The reduced set included epigenetic modifiers (for example, HMGN4 and 
SETD1B), transcriptional regulators (for example, MED13L) and hematopoietic transcription factors 
(for example, CEBPB). Indeed, network analysis (ingenuity pathway analysis) of these lincRNA 
targets identified 11 networks associated with ‘Hematological System Development’, ‘Hematological 
Disease’, Cancer and ‘Cell Death and Survival’ (Figure 1e, Supplementary Figure S5 and 
Supplementary Table S10), suggesting that some of the lincRNAs quantified by the standard array 
platform have an important role during hematopoiesis and in the regulation of gene expression. 
 
Cytogenetic and molecular subtypes of AML have distinct patterns of lincRNA expression 
Clinical outcomes in AML vary depending on cytogenetic and mutation status as well as patterns of 
mRNA and microRNA expression.20, 21 Extensive cytogenetic and mutational profiles were available 
for 419 patients in the NL and 178 patients in the USA sets, and we evaluated whether the expression 
of lincRNAs was also associated with these AML subtypes. Interestingly, an initial analysis revealed a 
surprising association of lincRNA expression patterns and gender across many of the established 
subgroups. Therefore, we computationally removed gender effects and identified 235 lincRNA genes 
with significant variation across the available cytogenetic and mutational profiles (analysis of variance; 
fold change >1.5; P-value<0.05). Hierarchical clustering of the 235 lincRNA genes in the NL (Figure 
2a) and USA sets (Figure 2b) identified distinct grouping effects in both cohorts, which were 
comparable to an equivalent analysis of coding genes (Supplementary Figures S6 and S7). In 
particular, we found that patients with t(8:21) and t(15;17)/FAB M3 leukemia and those with mutations 
in CEBPA, NPM1 and/or FLT3-ITD had distinct lincRNA profiles in both cohorts. We also found 
associations that were unique to one or the other data set, that is, FAB M2 and M5 in the NL and 
inv(16) in the USA set. Notably, patients with TP53 mutations also showed a distinct lincRNA 
expression profile (available only in the USA set, Figure 2b). 
 
Cytogenetic and molecular subtypes of AML have distinct patterns of lincRNA expression. (a) 
Hierarchical clustering of 235 lincRNAs in the NL set. (b) Hierarchical clustering of 235 lincRNAs in 
the US set. (c) Unsupervised NMF clustering of 1664 lincRNAs in the NL set (left) and patient 
subtypes enriched in each cluster (Fisher exact test; right). (d) Unsupervised NMF clustering of 1664 
lincRNAs in the USA set (left) and patient subtypes enriched in each cluster (Fisher exact test; right). 
*LR, low cytogenetic risk; *IR, intermediate cytogenetic risk; *HR, high cytogenetic risk; *Complex 
karyotype, greater or equal to three distinct karyotypic abnormalities. 
 
The full set of 1664 lincRNAs was further analyzed using unsupervised non-negative matrix 
factorization clustering in the NL and USA sets. The NL cohort optimally separated into four novel 
groups that were enriched for specific AML subtypes (Figure 2c; P<0.01; Fisher exact test; 
Supplementary Table S11). Similarly, the USA cohort was optimally separated into five groups, 
including cluster three (C3), which was associated with older patients, complex karyotype, del(7q), 
those in FAB M0 and mutations in EZH2, RUNX1 and TP53, while cluster five (C5) was associated 
with younger patients, chromosomal translocation t(8,21) and t(15;17)/FAB M3 and mutations in 
CEBPA (Figure 2d; P<0.01; Fisher’s exact test; Supplementary Table S12). These data showed that 
lincRNA profiles segregated with clinical subgroups, and some clusters were enriched for specific 
patient groups with either good or poor prognosis; together this suggested that lincRNAs might be of 
prognostic significance in AML. 
 
LincRNA expression and clinical outcome 
Although the predictive value of coding gene expression signatures has been reported across large 
independent multicentre cohorts,22, 32 evaluation of lincRNA expression signatures has thus far been 
limited to a single report in CN-AML in older (>60 years) patients.19 To redress this, we evaluated 
whether the expression levels of the 1664 lincRNAs were predictive of overall survival (OS) in patients 
from the NL (N=392), USA (N=167) and GER (N=135) cohorts for whom survival data were available. 
Univariate Cox-regression analysis identified 78 lincRNAs in the NL, 109 in the USA and 87 in the 
GER sets individually associated with OS (P<0.05; Figure 3a and Supplementary Table S13; 
Materials and Methods). ENSG00000260257 was the sole lincRNA associated with survival across all 
three patient cohorts. To examine these correlations with an alternate method, we reanalyzed these 
data using an unsupervised clustering approach (Materials and Methods). Assessment of OS by the 
Kaplan–Meier model identified 115 lincRNAs in the NL, 111 in the USA and 92 in the GER sets 
(P<0.05; Figure 3b and Supplementary Table S13; Materials and methods). While 
ENSG00000260257 was again identified, ENSG00000236537 emerged as a second lincRNA 
individually associated with OS across all three patient cohorts (Figure 3c). The expression of 
ENSG00000260257 and ENSG00000236537 correlated with adjacent coding genes MAPRE1 and 
TULP4. However, neither of these coding genes significantly associated with patient survival across 
all three patient cohorts (that is, mean P-values from Kaplan–Meier analysis: 0.28 and 0.11). The 
limited overlaps between these three patient cohorts were comparable (for example, there was no 
significant differences to these overlaps when coding genes instead of lincRNAs were considered 
P=0.5456, Fisher’s exact test) using an equivalent analysis performed with all 54 677 HG133P2 
probes (that is, including probes for coding genes) instead of the 1664 lincRNAs. Importantly, these 
data are consistent with earlier reports correlating individual coding gene expression levels with 
clinical data across multiple patient cohorts.33, 34 
 
LincRNA expression is associated with clinical outcome. (a) Venn diagram of univariate Cox-
regression analysis of patient OS in the NL, US and GER sets. ENSG00000260257 is shared 
between all three data sets. (b) Clustering/Kaplan–Meier analysis of patient OS. ENSG00000260257 
and ENSG00000236537 are shared between all three data sets. (c) Kaplan–Meier plots stratified by 
the two shared lincRNA genes ENSG00000260257 (top) and ENSG00000236537 (bottom). 
Full figure and legend (174K) 
 
By contrast, the expression levels of several genes in combination are a more powerful predictor of 
clinical outcome, and this has been harnessed to generate prognostic coding gene signatures in 
AML.22, 32, 35, 36, 37 However, these coding gene signatures require measuring between 17 and 133 
coding genes. Therefore, we set about identifying and evaluating combinations of lincRNAs, that is, 
lincRNA-sigs, as predictors of clinical outcome that apply across the US, NL and GER cohorts. 
Particularly, we aimed to evaluate whether measuring a smaller number of two to four lincRNAs could 
serve as an alternative to measuring large numbers of coding genes. 
 
LincRNA gene signatures are independent predictors of clinical outcome across multiple 
patient cohorts 
The expression levels of 25 and 28 individual lincRNAs were associated with OS in at least two of the 
three patient cohorts, assessed by Cox-regression and Kaplan–Meier statistics, respectively (P<0.05; 
Figures 3a and b). These included 43 unique lincRNAs (Supplementary Table S13) and, given their 
performance as individual prognosticators, we reasoned that combinations of these genes were likely 
to reveal lincRNA-sigs composed of only a small number of lincRNAs, which are predictive for OS 
across the NL, USA and GER cohorts. 
 
With the objective to minimize the number of lincRNAs in each lincRNA-sig, we incrementally 
screened combinations of two, three or four lincRNAs selected from the set of 43 lincRNAs. This 
limited the search space to 136 697 combinations (Figure 4a and Supplementary Figure S8; Materials 
and methods). Univariate Cox-regression and Kaplan–Meier analysis revealed that ~12% of the 
tested lincRNA-sigs (that is, 16491) were significantly associated with OS across all three patient 
cohorts, including 74, 1328 and 15 089 signatures composed of two, three and four lincRNAs, 
respectively (P<0.05; Figure 4a and Supplementary Table S14). In addition to outcome data, 
extensive clinical, cytogenetic and molecular data were available for 390 patients in the NL, 159 
patients in the USA and 116 patients in the GER cohorts. Therefore, we further interrogated the 
identified lincRNA-sigs in the context of these parameters (for example, age, gender and white blood 
cell count) and clinically useful cytogenetic and mutational data (for example, the four risk groups 
defined by the ELN7). Multivariate Cox-regression analysis showed that 201 or ~1.2% (of the 16 491) 
candidates remained independent predictors of OS across all three patient cohorts, including 15 and 
186 signatures composed three and four lincRNAs, respectively (Figure 4a and Supplementary Table 
S15). These lincRNA-sigs conferred increased risk of death that ranged from 29 to 62% (hazards ratio 
(HR): 1.29–1.62), 45 to 192% (HR: 1.45–2.92) and 55 to 142% (HR: 1.55–2.42) in the NL, USA and 
GER sets, respectively (Supplementary Tables S15). 
 
LincRNA gene signatures are independent predictors of clinical outcome. (a) Flowchart of the 
lincRNA-sig discovery pipeline. (b) LincRNAs were scored according to their frequency in the 201 
lincRNA-sigs significantly associated with patient overall survival. LincRNA-sigs were scored 
according to the mean frequency of their participating lincRNAs. The frequency distribution of the 
lincRNA-sig scores is shown. A single signature (LINC4) consisting of the four genes 
ENSG00000153363, XLOC_013473, ENSG00000255571 and ENSG00000260257 had the highest 
score (marked in red). (c) Application of LINC4 in the NL, USA and GER sets. (i) Principle component 
analysis of patients grouped (G1 and G2) by expression levels of these lincRNAs. (ii) Kaplan–Meier 
overall survival plots of patient groups G1 and G2. (iii) Multivariate Cox-regression OS tables for this 
lincRNA-sig (the prefix a was used to indicate the adjusted model parameters). (d) Application of 
LINC4 to patient subsets with ELN-FR, ELN INT-1, ELN INT-2 and ELN-AR in the NL cohort subtypes 
further dichotomizes patients with favorable and adverse risk profiles. (e) Overall survival of the TCGA 
cohort grouped using (i) the LSC17 signature. The low (ii) and high (iii) risk patients were further 
subgrouped using LINC4. (f) Overall survival of the German cohort grouped using (i) the LSC17 
signature. The low (ii) and high (iii) risk patients were further subgrouped using LINC4. 
Full figure and legend (470K) 
 
Interestingly, we found that XLOC_013473 was part of 38% (that is, 76), while ENSG00000227946 
and ENSG00000246985 only featured in one of the 201 lincRNA-sigs, indicating that some lincRNAs 
might contribute more to the observed prognostication than others (Supplementary Table S3). 
Therefore, we scored each of the 201 lincRNA-sig by the frequency of its contributing lincRNAs and 
found that the signature consisting of ENSG00000153363, XLOC_013473, ENSG00000255571 and 
ENSG00000260257 achieved the highest score (cummulative frequency of 233, ~29%; mean 
frequency 58.25; Figure 4b and Supplementary Table S4). Cluster analysis using expression levels of 
these four lincRNAs in healthy CD34+ cells and AML cell lines from CCLE showed distinct patterns of 
expression between healthy and leukemic cells (Supplementary Figures S9 and S10). In addition, we 
used data from BLUEPRINT (N=82; ref. 38) and the Cancer Cell Line Encyclopedia (N=31; ref. 39) to 
map the expression patterns of these lincRNAs in normal human stem and progenitor subsets and in 
AML cell lines. We then performed differential expression analysis using EdgeR for well-defined early 
hematopoietic transitions including HSC→ MPP, MPP → CMP, CMP → MEP, CMP → GMP and two 
MEP → MK/ERY, and compared the pool of CD34+ with CD34− populations and the pool of the 
CD34+ population with AML cell lines (Supplementary Table S16). We found that none of these six 
lincRNAs was associated with defined early hematopoietic transitions. However, ENSG00000255571 
was higher expressed in CD34− and AML cells when comparted with CD34+ cells. Similarly, 
ENSG00000153363 was more expressed in AML cells when compared with CD34+ cells. The 
lincRNA-sig composed of these four genes (hereafter referred to as LINC4) was then applied to the 
NL, USA and GER AML patient cohorts to evaluate its prognostic potential. Patients in all three 
cohorts clustered into distinct groups (Figure 4c(i)) and had significantly different OS (Figure 4c(ii)) 
with HRs that were often close to those achieved when the ELN IR-1, IR-2 and AR were assessed in 
reference to ELN-FR (for example, patients with favorable prognosis including t(8;21) or inv(16); 
Figure 4c(iii)). Importantly, when LINC4 was applied independently to patients classified as ELN-FR, 
IR-1, IR-2 or AR, it was able to further dichotomize patients in each ELN group into cohorts with 
significantly better or worse OS (Figure 4d and Supplementary Figure S11). 
 
Most recently, a study reported that a set of 17 coding genes was higher expressed in leukemic 
compared with normal blood stem cells and that a score comprising these 17 coding genes (that is, 
LSC17) was prognostic in multiple patient cohorts.32 We re-calculated the LSC17 score for the 
validation cohorts from the US and GER, and found that it dichotomized survival (Figure 4e(i) and f(i)). 
Strikingly, we found that application of LINC4 to the patient subsets with either high or low LSC17 
score further dichotomized patient survival in both the US (Figure 4e(ii, iii)) and GER cohorts (Figure 
4f(ii, iii)). This further suggests that LINC4 might capture pathways associated with patient survival, 
which are independent of the LSC17 score and hence LSC biology. 
 
RT-PCR-based validation of the four-gene signature 
Motivated by these results and to validate and facilitate application of LINC4, we sourced an 
additional patient cohort (AUS) to profile lincRNA expression using an orthogonal profiling method. In 
brief, we developed a Fluidigm RT-PCR-based assay that included a regression-based approach for 
data normalization (Materials and methods). We designed primer pairs for each of the LINC4 
lincRNAs ENSG00000153363, XLOC_013473, ENSG00000255571 and ENSG00000260257 and five 
reference genes that showed stable expression across the dynamic range of the 201 lincRNA-sigs 
(Supplementary Table S5 and Supplementary Figure S2, Materials and Methods). 
 
We applied this pipeline to a fourth large independent set of 113 primary AMLs with extensive clinical, 
cytogenetic and molecular data (AUS set, Supplementary Table S1). Expression profiles were in the 
range expected from the array analysis of the NL, USA and GER cohorts (Figure 5a), and patients 
were well separated into two distinct groups (Figure 5b). Logistic regression with leave-one-out and 
10-fold cross-validation confirmed that patients could be dichotomize into those with favorable (LINC4 
Fav; longer OS) and adverse (LINC4 Adv; shorter OS) prognosis with perfect sensitivity and 
specificity (Figure 5c) following: 
, where G1 is the 
normalized expression of ENSG00000153363, G2 of XLOC_013473, G3 of ENSG00000255571 and 
G4 of ENSG00000260257. Further interrogation of the two identified patient groups using 
multivariable Cox-regression analysis (including gender, age, wbc and ELN) confirmed that LINC4 
was also an independent predictor of OS in the AUS cohort conferring an increased risk of death of 
197% (HR: 2.96; P-value=0.00548; Figure 5d). 
 
RT-PCR-based assay confirms the association of lincRNA-sigs in AUS cohort. (a) Expression levels 
of ENSG00000153363, XLOC_013473, ENSG00000255571 and ENSG00000260257 (LINC4) and 
five control primers in the AUS set measured by RT-PCR. (b) Application of LINC4 to the AUS cohort 
identifies two patient groups. (c) Logistic regression was used to delineate the two patient groups. 
The regression model was validated using cross-validation and receiver operating characteristic 
analysis. (d) Multivariate Cox-regression table of patient OS (the prefix a was used to indicate the 
adjusted model parameters). 
Full figure and legend (150K) 
 
Discussion 
LincRNAs are emerging as key regulators of many biological processes and are widely studied in 
solid tumors.12, 13 However, very little is known about their expression, function or potential as 
prognosticators in leukemias. To gain insights into their role and to evaluate whether existing data 
warrant further investigation of these genes in AML, we developed and validated a novel approach to 
quantify the expression of 1664 lincRNAs in 736 AML patients from three well-characterized patient 
cohorts. Interrogation of this database with matched expression profiles of coding genes reconfirmed 
previously known regulatory relationships, and uncovered 263 novel lincRNA–coding gene 
relationships. This unbiased list of in silico predictions was valid across three patient cohorts and 
warrants further experimental/functional validation. 
 
In a univariate survival analysis, we found that 43 lincRNAs were associated with OS in at least two 
patient cohorts. Screening our database for biomarker panels of up to four lincRNAs, we identified 
201 distinct lincRNA-sigs associated with OS across all three patient cohorts. A recent study reported 
the association of 48 lncRNAs (including 10 lincRNAs), with OS in a cohort of 148 CN-AMLs aged 
over 60 years.19 Four of these 10 lincRNAs were among the 1664 lincRNAs detectable by HG133P2 
arrays, but none was significantly associated with OS in the three AML cohorts analyzed in our study 
(Supplementary Table S17). Overall, these data suggest that prognostic markers derived merely from 
in silico analysis of single trial cohorts risk identifying trial-specific rather than broadly applicable and 
biologically significant risk factors. In contrast, we report that a prognostic marker composed of four 
lincRNAs—ENSG00000153363, XLOC_013473, ENSG00000255571 and ENSG00000260257—was 
an independent predictor of OS across four patient cohorts, including an independent test cohort of 
113 AML patients profiled by high-throughput RT-PCR. 
 
However, given the poor functional annotation of lincRNAs in general, it is still unclear whether these 
particular lincRNAs have a direct role in the pathogenesis and/or maintenance of leukemia or are 
merely a surrogate readout for a transcriptional milieu that makes leukemic cells sensitive to current 
treatment. We want to note that, although the expression levels of all four components of the lincRNA-
sig constitute its prognostic power, understanding their individual functions will further provide insights 
into their value as therapeutic targets. For example, we have profiled the expression of these genes at 
six transitions during normal hematopoiesis, and could show that neither of these genes associated 
with well-established transition points. However, ENSG00000153363 and ENSG00000255571 are 
specifically upregulated in leukemic cells, and this warrants further functional experiments to test 
whether reducing the expression of ENSG00000153363 and/or ENSG00000255571 affects leukemic 
cells. 
 
The ELN 2017 iteration incorporates recent updates to the World Health Organization classification,40 
but unlike ELN 2010, which was used in this study, is yet to be applied to AML cohorts with 
longitudinal data. It now employs a three-group classification (favorable, intermediate and adverse), 
by merging of intermediate-I and -II groups, where the distinctions were mostly genetic rather than 
prognostic. AML with biallelic mutated CEBPA is now recognized as favorable, mutations in RUNX1, 
ASXL1 and TP53 as well as monosomal karyotype are recognized as adverse and consideration is 
given to the FLT3-ITD mutant/allele ratio.41 Treatment recommendations for AML patients with 
favorable (ELN-FR) risk would usually be standard chemotherapy unlike those with an unfavorable 
(ELN-AR) risk who would be considered for allogenic bone marrow transplantation.42 On the other 
hand, patients with intermediate-risk profiles (ELN IR-1 and ELN IR-2) pose a clinical conundrum. The 
NL cohort was unique among the four AML cohorts in having sufficiently large patient numbers in 
each ELN risk group for us to apply the lincRNA-sig to all groups (Figure 4d). On the evidence shown 
here, the lincRNA-sig could be a useful adjunct to clinical decision-making. The adverse arms in the 
intermediate-risk groups as dichotomized by the lincRNA-sig mirrors ELN adverse risk, and these 
patients may need to be considered for allogeneic bone marrow transplantation. Conversely, those 
dichotomized into the favorable arm could possibly be spared an unnecessary transplant. 
 
The purpose of this study was to explore the expression of lincRNAs in the best clinically annotated 
AML data sets that have formed the foundation of a large body of existing research, and thus limited 
our analysis to evaluate 1664 poly (A) + lincRNAs. Like others, we show that lincRNAs are often 
relatively low expressed transcripts and consequently might not be not be well represented in non-
targeted and low-coverage transcriptomic studies using RNA-seq (that is, including poly (A) + RNA-
seq by the TCGA). In addition, lincRNAs might also be transcribed from antisense loci of coding 
genes, and thus be difficult to resolve by non-strand-specific transcriptomes measured by RNA-seq 
(that is, RNA-seq by the TCGA). Interestingly, the ENCODE project reported the widespread 
expression of non-coding poly (A)–transcripts, suggesting that poly (A)–lincRNAs might also exist in 
AML.11 This suggests that an unknown number of novel lincRNAs is expressed in AML, and our 
investigation of a small subset of lincRNAs further implies that some of these are relevant during 
leukemogenesis and/or have prognostic value. We believe that deep sequencing followed by targeted 
sequencing of strand-specific libraries from poly (A) + and poly (A)–transcripts, which fulfill the criteria 
for lincRNAs, in prospective clinical trials will further refine and translate the signatures that we have 
described in this manuscript.43 
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